Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

Launched by FUJIAN CANCER HOSPITAL · Jul 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying new treatment options for people with metastatic colorectal cancer (mCRC) that started in the left side of the colon or rectum. Specifically, it is comparing two different chemotherapy combinations, each combined with an immunotherapy drug called QL1706, to see which works better and is safer as a first treatment. The goal is to find out if adding QL1706 to these chemotherapy plans can help control the cancer more effectively.

People eligible for this study are adults aged 18 to 75 who have left-sided metastatic colorectal cancer that has specific genetic features (called RAS and BRAF wild-type). They must be in generally good health, able to perform daily activities, and have not received prior treatment for their advanced cancer. If accepted into the trial, participants will be randomly assigned to one of two treatment groups, both receiving chemotherapy every two weeks for up to nine cycles, along with the immunotherapy QL1706 every three weeks for up to a year. After these treatments, doctors will decide on further maintenance therapy if needed. Participants will be closely monitored through imaging tests and health evaluations to assess how well the treatment is working and to watch for side effects. The study will continue until the treatment no longer helps, side effects become too severe, or the participant chooses to stop. This trial offers a chance to try promising new treatment combinations under careful medical supervision.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 to 75 years old.
• • 2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
• • 3. Histologically or cytologically confirmed metastatic colorectal adenocarcinoma with the primary tumor located in the left-sided colon (from the splenic flexure to the rectum), including cecal adenocarcinoma.
• • 4. Presence of at least one evaluable lesion according to RECIST v1.1 criteria.
• • 5. The subject has provided sufficient tumor tissue samples through colonoscopy biopsy for MSI, TMB, and other tests.
• • 6. Tumors confirmed by tissue testing to be wild-type for KRAS, NRAS, and BRAF.
• • 7. Within 7 days prior to the first dose of study drug, laboratory tests meet the following criteria (no blood products, hematopoietic growth factors, albumin, or other corrective treatments within 14 days prior to testing): (1) Biochemistry: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN), or ≤ 5 times ULN in the presence of liver metastases; total bilirubin (TBIL) ≤ 1.5 times ULN, or ≤ 2 times ULN in the presence of liver metastases; serum creatinine ≤ 1.5 times ULN, or creatinine clearance \> 50 mL/min (calculated by the Cockcroft-Gault formula). (2) Hematology: Hemoglobin (Hb) ≥ 9.0 g/dL. No red blood cell transfusions within 1 week prior to the baseline Hb test; absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelet count ≥ 100 × 10⁹/L. No platelet transfusions within 1 week prior to the baseline platelet test. (3) Coagulation function: International normalized ratio (INR) ≤ 1.5 × ULN (for subjects receiving prophylactic anticoagulation therapy without active bleeding \[i.e., no bleeding within the past 14 days\], the investigator should determine that the INR is within a safe and effective therapeutic range). (4) Urinalysis: Urine protein ≤ 30 mg/dL (1+) by dipstick or routine urinalysis (if ≥ 2+, then a 24-hour urine protein quantification must be \< 1 g/24h).
• • 8. Estimated survival of at least 3 months.
• • 9. No contraindications to chemotherapy or immunotherapy.
• • 10. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrollment and agree to use a reliable and effective method of contraception during the study and for 5 months after the last dose of study drug. Men whose partners are women of childbearing potential must agree to use a reliable and effective method of contraception during the study and for 5 months after the last dose of study drug. Lactating women are not eligible.
• • 11. The subject must provide informed consent for the study prior to enrollment, voluntarily sign a written informed consent form, and be willing and able to comply with the study visit schedule, treatment plan, laboratory tests, and other study procedures.
• Exclusion Criteria:
• • 1. Confirmed by histopathological or cytological examination as other pathological types, such as squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, etc. For mixed pathological types, the determination will be made based on the predominant component; adenocarcinoma component \> 70% confirmed by pathologist is eligible for enrollment. Primary appendiceal tumors are exclusion criteria.
• • 2. Presence of other active malignancies within the past 3 years, except for early malignancies that have been cured (carcinoma in situ or stage I tumors), such as adequately treated cervical carcinoma in situ, thyroid cancer, basal cell or squamous cell carcinoma of the skin, etc.
• • 3. Previous systemic therapy for unresectable/metastatic colorectal cancer.
• • 4. Active autoimmune disease within the past 2 years requiring systemic treatment (i.e., immunomodulatory drugs, corticosteroids, or immunosuppressive agents); however, replacement therapy (e.g., thyroid hormone, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) will not be considered systemic treatment and is permitted.
• • 5. Presence of immunodeficiency or receipt of long-term systemic corticosteroid therapy (daily dose \> 10 mg prednisone or equivalent corticosteroid) within 7 days prior to enrollment, or other immunosuppressive therapy.
• • 6. Uncontrolled diabetes mellitus; peripheral neuropathy ≥ Grade 2.
• • 7. Active tuberculosis, or receipt of anti-tuberculosis treatment within 1 year prior to enrollment.
• • 8. If hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) are positive, the patient's HBV-DNA must be less than 500 IU/mL. For patients with active hepatitis B, the patient must have received antiviral therapy for at least 14 days prior to enrollment (according to local standard treatment, such as entecavir or tenofovir) and agree to continue effective antiviral therapy during the study.
• • 9. If HCV antibody is positive, HCV-RNA testing will be performed; if HCV-RNA \> 1,000 copies/mL, the patient will be excluded.
• • 10. Receipt of any live vaccine within 28 days prior to enrollment (e.g., vaccines for infectious diseases, such as influenza vaccine, varicella vaccine, etc.).
• • 11. Previous allogeneic bone marrow transplant or solid organ transplant.
• • 12. Major surgery within 4 weeks prior to the first dose, or significant trauma, or presence of a wound that has not healed or healed poorly or complications in wound management.
• • 13. Known allergy to any component of the study drug; known multiple allergies or history of severe allergic diseases.
• • 14. Systemic anti-infective therapy within 2 weeks prior to the first dose.
• • 15. Receipt of nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants within 7 days prior to the first dose or ongoing.
• • 16. Active infectious diseases, such as HIV/AIDS or active syphilis.
• • 17. Use of any other investigational drug within 28 days prior to randomization or participation in another investigational drug trial.
• • 18. Clinically significant underlying medical conditions that may affect the administration of the study drug or compliance with the protocol, as judged by the investigator.
• • 19. Known history of psychiatric illness, drug abuse, alcoholism, or drug addiction.
• • 20. Pregnant or breastfeeding women.
• • 21. Other individuals deemed inappropriate for enrollment by the investigator.